Navigation Links
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
Date:5/5/2008

Q8003IR Met Primary Endpoints; Demonstrated Strong Reduction of Pain Intensity

SYDNEY, Australia and BEDMINSTER, N.J., May 5

/PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today initial Phase 3 efficacy results for Q8003IR, an immediate release dual-opioid product intended for the acute management of moderate to severe pain.

"Initial Phase 3 efficacy data demonstrated statistically significant analgesic activity at all doses tested and reinforces the potential clinical benefit and commercial value of QRxPharma's lead dual-opioid product," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "We are pleased with this study outcome and believe that it demonstrates that the Company remains on target to complete clinical testing for Q8003IR, submit a New Drug Application (NDA) in 2009 and achieve its goal of product launch in 2010."

The double-blind, placebo-controlled study was designed to compare the efficacy and safety of four different dosage regimens of Q8003IR, a fixed ratio morphine/oxycodone combination. 256 patients with moderate to severe pain following surgery (bunionectomy) completed the trial, and it was conducted at six US clinical research sites. The primary efficacy analysis compared the change in pain intensity scores over the 48 hr dosing period (SPID48) in patients receiving Q8003IR vs. placebo.

Among all patients receiving Q8003IR, approximately 50% reported good to excellent global improvement (vs. 13% for placebo) and demonstrated a strong dose-response effect (p<0.001) in reducing pain intensity scores [i.e. the sum of pain intensity difference over 48 hours relative to the first dose (SPID48)] and other measures of analgesic effect. Per treatment group, median doses received every 4 hours
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
3. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
4. Immunosyn Corporation Releases SF-1019 Study Results
5. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
6. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
10. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015  SillaJen, Inc., a ... of oncolytic immunotherapy products for cancer, today announced ... the Annual Meeting of the American Association for ... murine adapted version of its lead product candidate, ... is an oncolytic immunotherapy designed to 1) rapidly ...
(Date:4/20/2015)... , April 20, 2015 The preclinical contract research ... testing of drugs and safety testing of medical devices, announces ... at this week,s workshop " Drug Transporters in ADME: From ... MD . The title of Dr. Hidalgo,s talk is ... a session entitled "Transporter Tools of the Future." ...
(Date:4/20/2015)... , April 20, 2015   Gateway ... Research and Training Institute today expanded its Naloxone: ... outpatient locations.  A $50,000 grant from the ... research project possible.  The yearlong ... to patients and their family members upon completion ...
Breaking Medicine Technology:SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 3Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 3
... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... , A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
... , EMERYVILLE, Calif., Dec. 4 ... it will host an investor teleconference and webcast. Principal ... and/or refractory multiple myeloma, as featured at the 51st American ... begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December ...
Cached Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2
(Date:4/20/2015)... Bronx, NY (PRWEB) April 20, 2015 The ... are introducing the community to Bella Diosa Laser Med Spa ... invited to a spa party on from 12–7 p.m. on ... The event will include drinks and refreshments. Participants will also ... Attendees will receive a free gift with any purchase, as ...
(Date:4/20/2015)... is a seemingly idyllic and tranquil island oasis in ... off the southeastern coast of Africa, the tiny nation ... everyone lives together in harmony. , But the shimmering ... drug abuse. In fact, it carries a dubious designation: ... in eastern Africa. , “Many youngsters, they know the ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 At the ... held the “RockNRolla Movie Awards” EcoLuxe Lounge, with Choices ... Angeles’ leading producer of sustainable product placement in TV ... of socially conscious and ecologically sound goods and services ... star Chase Masterson hosted the Choices Celebrity Interview Lounge, ...
(Date:4/20/2015)... Connecticut (PRWEB) April 20, 2015 ... Moreen Donahue, DNP, RN, NEA-BC, FAAN who was ... Nursing Education and Research in September 2014, is ... Nursing Officer to lead the development of Western ... this newly created role, Donahue will be responsible ...
(Date:4/20/2015)... 2015 The normal response from the doctor ... we could do.” Especially if the patient sought medical care ... should be much different. So it’s critical the patient’s loved ... be done?” , Not every emergency room physician or ... can be done.” But, according to Ronald P. Benitez ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Says Hello to Yonkers Community with Spa Party 2Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3
... ... wellness. Learn how to improve the look and strength of your abdominal muscles and improve ... on this new Web site. , ... June 17, 2010 -- A new Web site has been developed to help anyone get in ...
... ... to Bring Fresh, Locally Sourced, All-Natural Snacks and Beverages to Kicks 4 Kids Community ... ... First Soccer and the McHenry Area Soccer Federation have partnered with McHenry’s Healthy U ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is a great deal of interest in factors that contribute ... One factor that appears to contribute to the heritable ... codes for the serotonin transporter, also known as the serotonin ... transporter gene appears to increase one,s risk for depression and ...
... role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein ... a robust, non-invasive predictor of cardiovascular (CV) risk in ... by the results of a multinational study presented today ... League Against Rheumatism in Rome, Italy. The presence ...
... Grant to ... Athletes , ... June 17, 2010 -- Athletes for Hope (AFH), an entrepreneurial non-profit founded by 12 of ... purpose of inspiring all athletes to engage in positive social impact, has been awarded a ...
Cached Medicine News:Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 3Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 4Health News:PTSD: The serotonin system influences vulnerability and treatment 2Health News:NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Disposable Cannula Cuffed Tracheostomy Tubes...
Medicine Products: